Page 266 - Read Online

Cao Cancer Evo-Dev

2013;500:415-21. carcinoma. Nat Genet 2012;44:1117-21.
97. Kuong KJ, Loeb LA. APOBEC3B mutagenesis in cancer. Nat Genet 115. Wong CM, Fan ST, Ng IO. Beta-Catenin mutation and overexpression
2013;45:964-5. in hepatocellular carcinoma: clinicopathologic and prognostic
98. Liu WB, Wu JF, Du Y, Cao GW. Cancer Evolution-Development: significance. Cancer 2001;92:136-45.
experience of hepatitis B virus-induced hepatocarcinogenesis. Curr 116. Yeh SH, Chiu CM, Chen CL, Lu SF, Hsu HC, Chen DS, Chen PJ.
Oncol 2016;23:e49-56. Somatic mutations at the trinucleotide repeats of androgen receptor
99. Deng Y, Du Y, Zhang Q, Han X, Cao G. Human cytidine deaminases gene in male hepatocellular carcinoma. Int J Cancer 2007;120:1610-7.
facilitate hepatitis B virus evolution and link inflammation and 117. Han YF, Zhao J, Ma LY, Yin JH, Chang WJ, Zhang HW, Cao GW.
hepatocellular carcinoma. Cancer Lett 2014;343:161-71. Factors predicting occurrence and prognosis of hepatitis-B-virus-related
100. Ji X, Zhang Q, Du Y, Liu W, Li Z, Hou X, Cao G. Somatic mutations, hepatocellular carcinoma. World J Gastroenterol 2011;17:4258-70.
viral integration and epigenetic modification in the evolution of 118. Cao GW. Clinical relevance and public health significance of hepatitis
hepatitis B virus-induced hepatocellular carcinoma. Curr Genomics B virus genomic variations. World J Gastroenterol 2009;15:5761-9.
2014;15:469-80. 119. Chen LP, Zhao J, Du Y, Han YF, Su T, Zhang HW, Cao GW. Antiviral
101. Gatenby RA, Gillies RJ, Brown JS. Of cancer and cave fish. Nat Rev treatment to prevent chronic hepatitis B or C–related hepatocellular
Cancer 2011;11:237-8. carcinoma. World J Virol 2012;1:174-83.
102. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 120. Kumar R, DiMenna L, Schrode N, Liu TC, Franck P, Muñoz-Descalzo
2010;10:181-93. S, Hadjantonakis AK, Zarrin AA, Chaudhuri J, Elemento O, Evans T.
103. Xu X, Chen W, Zhang L, Miao R, Zhou Y, Wan Y, Dong Y, Liu AID stabilizes stem-cell phenotype by removing epigenetic memory
C. Prognostic significance of neutrophil to lymphocyte ratio in of pluripotency genes. Nature 2013;500:89-92.
patients with hepatocellular carcinoma after transcatheter arterial 121. Nabel CS, Jia H, Ye Y, Shen L, Goldschmidt HL, Stivers JT, Zhang
chemoembolization. Chin Med J (Engl) 2014;127:4204-9. Y, Kohli RM. ID/APOBEC A deaminases disfavor modified cytosines
104. Peng W, Li C, Wen TF, Yan LN, Li B, Wang WT, Yang JY, Xu MQ. implicated in DNA demethylation. Nat Chem Biol 2012;8:751-8.
Neutrophil to lymphocyte ratio changes predict small hepatocellular 122. Muñoz DP, Lee EL, Takayama S, Coppé JP, Heo SJ, Boffelli D, Di
carcinoma survival. J Surg Res 2014;192:402-8. Noia JM, Martin DI. Activation-induced cytidine deaminase (AID)
105. Janahi EM, McGarvey MJ. The inhibition of hepatitis B virus by is necessary for the epithelial-mesenchymal transition in mammary
APOBEC cytidine deaminases. J Viral Hepat 2013;20:821-8. epithelial cells. Proc Natl Acad Sci U S A 2013;110:E2977-86.
106. Kitamura K, Wang Z, Chowdhury S, Simadu M, Koura M, 123. Rogozin IB, Lada AG, Goncearenco A, Green MR, De S, Nudelman
Muramatsu M. Uracil DNA glycosylase counteracts APOBEC3G- G, Panchenko AR, Koonin EV, Pavlov YI. Activation induced
induced hypermutation of hepatitis B viral genomes: excision repair deaminase mutational signature overlaps with CpG methylation sites
of covalently closed circular DNA. PLoS Pathog 2013;9:e1003361. in follicular lymphoma and other cancers. Sci Rep 2016;6:38133.
107. Morisawa T, Marusawa H, Ueda Y, Iwai A, Okazaki IM, Honjo T, 124. Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder
Chiba T. Organ-specific profiles of genetic changes in cancers caused D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela
by activation-induced cytidine deaminase expression. Int J Cancer I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine
2008;123:2735-40. K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene
108. Endo Y, Marusawa H, Kinoshita K, Morisawa T, Sakurai T, Okazaki B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward
IM, Watashi K, Shimotohno K, Honjo T, Chiba T. Expression of J, Futreal PA, Swanton C. Intratumor heterogeneity and branched
activation-induced cytidine deaminase in human hepatocytes via NF- evolution revealed by multiregion sequencing. N Engl J Med
κB signaling. Oncogene 2007;26:5587-95. 2012;366:883-92.
109. Amaddeo G, Cao Q, Ladeiro Y, Imbeaud S, Nault JC, Jaoui D, Gaston 125. Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins
Mathe Y, Laurent C, Laurent A, Bioulac-Sage P, Calderaro J, Zucman- TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, Salm
Rossi J. Integration of tumour and viral genomic characterizations in M, Horswell S, Escudero M, Matthews N, Rowan A, Chambers T,
HBV-related hepatocellular carcinomas. Gut 2015;64:820-9. Moore DA, Turajlic S, Xu H, Lee SM, Forster MD, Ahmad T, Hiley
110. Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, CT, Abbosh C, Falzon M, Borg E, Marafioti T, Lawrence D, Hayward
Stojanov P, Kiezun A, Kryukov GV, Carter SL, Saksena G, Harris S, M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A,
Shah RR, Resnick MA, Getz G, Gordenin DA. An APOBEC cytidine Blackhall F, Summers Y, Shah R, Joseph L, Quinn AM, Crosbie PA,
deaminase mutagenesis pattern is widespread in human cancers. Nat Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen
Genet 2013;45:970-6. H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam
111. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M,
IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, Clément B, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H,
Balabaud C, Chevet E, Laurent A, Couchy G, Letouzé E, Calvo Davies H, Dentro S, Taniere P, O’Sullivan B, Lowe HL, Hartley JA,
F, Zucman-Rossi J. Integrated analysis of somatic mutations and Iles N, Bell H, Ngai Y, Shaw JA, Herrero J, Szallasi Z, Schwarz RF,
focal copy-number changes identifies key genes and pathways in Stewart A, Quezada SA, Le Quesne J, Van Loo P, Dive C, Hackshaw
hepatocellular carcinoma. Nat Genet 2012;44:694-8. A, Swanton C; TRACERx Consortium. Tracking the evolution of
112. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz Jr.LA, non-small-cell lung cancer. N Engl J Med 2017;376:2109-21.
Kinzler KW. Cancer genome landscapes. Science 2013;339:1546-58. 126. Swanton C, McGranahan N, Starrett GJ, Harris RS. APOBEC
113. Li M, Zhao H, Zhang X, Wood LD, Anders RA, Choti MA, Pawlik enzymes: mutagenic fuel for cancer evolution and heterogeneity.
TM, Daniel HD, Kannangai R, Offerhaus GJ, Velculescu VE, Wang L, Cancer Discov 2015;5:704-12.
Zhou S, Vogelstein B, Hruban RH, Papadopoulos N, Cai J, Torbenson 127. Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard
MS, Kinzler KW. Inactivating mutations of the chromatin remodeling B, Refsland EW, Kotandeniya D, Tretyakova N, Nikas JB, Yee D,
gene ARID2 in hepatocellular carcinoma. Nat Genet 2011;43:828-9. Temiz NA, Donohue DE, McDougle RM, Brown WL, Law EK,
114. Huang J, Deng Q, Wang Q, Li KY, Dai JH, Li N, Zhu ZD, Zhou B, Liu Harris RS. APOBEC3B is an enzymatic source of mutation in breast
XY, Liu RF, Fei QL, Chen H, Cai B, Zhou B, Xiao HS, Qin LX, Han cancer. Nature 2013;494:366-70.
ZG. Exome sequencing of hepatitis B virus-associated hepatocellular 128. de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates

258 Hepatoma Research ¦ Volume 3 ¦ October 27, 2017